Sustained Release Excipients Market Performance and Future Outlook at 5.6% CAGR Through 2029

Uncover key drivers, emerging technologies, and competitive movements shaping the sustained release excipients market from 2025–2034 with trusted insights from The Business Research Company

What Is The Predicted Size Of The Sustained Release Excipients Industry By 2029?

The leukotriene modifiers market size has experienced significant expansion in recent years. This market is projected to grow from $22.33 billion in 2024 to $23.54 billion in 2025, at a compound annual growth rate (CAGR) of 5.4%. The historical growth of this market can be attributed to several factors, including the increasing influence of regulatory approvals, enhanced awareness among healthcare professionals and patients regarding the advantages of leukotriene modifiers, the expiration of patents for specific leukotriene modifier drugs enabling the introduction of generic alternatives, the expansion of indications for leukotriene modifiers, and increasing collaborations between pharmaceutical companies and healthcare organizations.

The leukotriene modifiers market is projected to experience substantial expansion in the coming years. This market is predicted to reach “$29.25 billion by 2029, exhibiting a compound annual growth rate (CAGR) of 5.6%. This anticipated growth during the forecast period is primarily driven by considerable opportunities in developing markets, stemming from advancements in healthcare infrastructure and greater disposable incomes. Other contributing factors include a move towards personalized medicine, the expanding use of telemedicine and remote patient monitoring, continuous research and development into new drug candidates and formulations, and expected shifts in regulatory policies. Key trends projected for this period encompass the incorporation of digital health technologies like mobile applications and wearable devices, the integration of artificial intelligence (AI) and machine learning algorithms, the investigation of new therapeutic targets, the creation of patient engagement solutions and tools, and the implementation of continuous manufacturing methods to enhance efficiency and adaptability in drug production.

Access A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=16109&type=smp

What Major Drivers Are Impacting The Sustained Release Excipients Market?

The escalating occurrence of asthma and allergic conditions is projected to stimulate the growth of the leukotriene modifier market moving forward. These conditions are characterized as a collection of disorders where the immune system exhibits hypersensitivity reactions to various allergens, leading to inflammation and other symptoms. The rising prevalence of asthma and allergic conditions can be linked to increased exposure to pollutants, warmer temperatures, fluctuating weather patterns, and higher population density. Leukotriene modifiers aid in managing and alleviating the symptoms of asthma and allergic conditions, simultaneously improving overall respiratory function, reducing inflammation, and offering a safer and more effective treatment alternative for patients dealing with chronic respiratory issues. For example, in May 2024, data published by the National Center for Health Statistics (NCHS), a U.S.-based health statistics agency, indicated that the prevalence of current asthma among adults aged 18 and over in the United States increased from 8.4% in 2021 to 8.7% in 2022. Additionally, the incidence of asthma episodes in the past 12 months for adults in the identical age group rose from 3.3% in 2021 to 3.7% in 2022. Thus, the increasing incidence of asthma and allergic conditions is a primary driver for the leukotriene modifier market.

Which Segment Categories Are Driving Maximum Growth In The Sustained Release Excipients Market?

The leukotriene modifiers market covered in this report is segmented –

1) By Drug Type: Montelukast, Zafirlukast, Zileuton ER, Zileuton

2) By Form: Tablets, Chewable Tablets, Oral Granules

3) By Distribution Channel: Hospitals Pharmacies, Retail Pharmacies, Drug Stores, Online Pharmacies

Subsegments:

1) By Montelukast: Tablet Formulation, Chewable Tablet Formulation, Oral Granules

2) By Zafirlukast: Tablet Formulation

3) By Zileuton ER: Extended-Release Tablet Formulation

4) By Zileuton: Tablet Formulation, Oral Suspension Formulation

Which Long-Term Trends Will Play A Crucial Role In The Sustained Release Excipients Market?

Leading companies operating within the leukotriene modifier market are concentrating on developing generic formulations, particularly extended-release (ER) tablets, to expand their product offerings and satisfy the growing demand for more convenient and effective treatment options. Generic extended-release (ER) tablets are pharmaceutical preparations of medicines designed to gradually release their active ingredients over an extended period, typically offering greater convenience and improved dosing schedules when compared to immediate-release formulations. As an illustration, in April 2023, Camber Pharmaceuticals Inc., a US-based pharmaceutical company, introduced Zileuton ER Tablets to its product line. These tablets are prescribed for the prevention and long-term treatment of asthma in adults and children 12 years and older. The tablets are not intended to reverse bronchospasm during acute asthma attacks but can be maintained during acute exacerbations of asthma. Zileuton ER Tablets are supplied in 600 mg strength within 120-count bottles.

Who Are The Dominant Players In The Sustained Release Excipients Market Today?

Major companies operating in the leukotriene modifiers market are Merck And Co., Sanofi SA, AstraZeneca PLC, Novartis AG, GlaxoSmithKline plc, Boehringer Ingelheim International GmbH, Viatris Inc., Teva Pharmaceutical Industries Ltd., Hetero Drugs Limited, Sun Pharmaceutical Industries, Sumitomo Dainippon Pharma, Chiesi Farmaceutici S.p.A., Cipla Limited, Aurobindo Pharma Limited, Dr. Reddy’s Laboratories, Apotex Pharmaceutical Holdings Inc., Torrent Pharmaceuticals Ltd., DAVA Pharmaceuticals, Alembic Pharmaceuticals Ltd., Starallergens Greer Ltd, Lannett Company, Accord Healthcare, Jubilant Life Sciences Ltd., Aytu BioScience, Annett Company Inc.

Download The Full Report Here:

https://www.thebusinessresearchcompany.com/report/leukotriene-modifiers-global-market-report

Which Region Is At The Forefront Of Innovation In The Sustained Release Excipients Market?

North America was the largest region in the leukotriene modifiers market in 2024. The regions covered in the leukotriene modifiers market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Get A Report Customized For You Here:

https://www.thebusinessresearchcompany.com/customise?id=16109&type=smp

Browse Through More Reports Similar to the Global Sustained Release Excipients Market 2025, By The Business Research Company

Progressive Multifocal Leukoencephalopathy Treatment Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/progressive-multifocal-leukoencephalopathy-treatment-global-market-report

Leukocyte Adhesion Deficiency Management Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/leukocyte-adhesion-deficiency-management-global-market-report

Impact Modifiers Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/impact-modifiers-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795